Get yourself updated on key emerging technology markets

Know about our market intelligence coverage in key sectors

Product is added to your Wishlist
Global In-Vitro Diagnostics (IVD) Market

Global In-Vitro Diagnostics (IVD) Market: Analysis and Forecast 2017-2023 (Focus on Product Type, Test Type, Application, and Competitive Landscape)

IVD is expected to increase to $76 billion by 2023 and increase its influence over healthcare spending globally. The category’s rate of growth is accelerating due to a number of key macro forces, such as demand from emerging economies, aging population, evolving clinician attitudes, and a much needed push towards theranostics and personalized medicine.

SKU: BH016A
Published Year: 2017
 
 

In-Vitro diagnostics (IVD) is a broad term which refers to the use of medical devices and accessories in order to perform wide ranging tests on bodily fluids such as blood, urine, tissue etc. Consequently, these tests provide meaningful insights about the health of a human body. IVDs may aid in either the detection of an infection, diagnosis of a medical condition, preventing a disease or monitoring the effectiveness of a drug therapy. IVD tests may vary from simple to sophisticated formats including reagents, calibrators, control materials, kits, software, and related instruments.                                                           

Moreover, IVDs also differ in terms of their usage, for example: some tests are performed under a clinical/laboratory setting while others can be purchased over-the-counter (OTC) and performed at home with ease by the user.  Under the IVD umbrella, there are wide range of segments which have been discussed in this report for instance, molecular diagnostics, clinical chemistry, immunochemistry/immunoassay, coagulation and hemostasis. 

In spite of enormous competition levels that prevails in the industry, the market growth is expected to be propelled by multiple factors such as rising prevalence of infectious and chronic diseases, upsurge in the government spending on healthcare, and ever rising population base to name a few. The market is expected to witness a substantial growth in the emerging countries such as India, China, and Brazil owing to significant healthcare initiatives by local governments and rising health related awareness among people

The research study has segmented the entire IVD market into product and services type, technology, application and geographical region which enables the user gain a multi-dimensional view of the market. Geographically, the report identifies North America as the leading market in the industry owing to the advanced nature of the healthcare systems in United States and Canada, rising adoption rates of technologically advanced products and increase in the rate of acceptance of precision medicine. 

The research report employs an exhaustive and analytical approach to estimate and understand the market thus provides an all-inclusive insight into various forms of developments, market trends and strategies. While underlining the key driving and restraining factors for the IVD market, the report also provides a comprehensive understanding in terms of competitive landscape, market share analysis, competitor benchmarking (matrices), and their positioning within the global in-vitro diagnostics market.

The following questions have been answered in this report:
•    What are the major market drivers, challenges and opportunities of the global in-vitro diagnostics market and their use cases?
•    What are the drivers and restraints that influences the growth of the global in vitro diagnostics market?
•    What is the market share of the leading segments and sub-segments of the global in-vitro diagnostics market during the forecast period (2017-2022)?
•    How will each segment of the global in-vitro diagnostics market grow over the forecast period and the revenue share for each of them by the end of 2022?
•    Who are the leading players in the global in-vitro diagnostics market (2016 & 2017)?
•    Which geographical region will have the highest growth rate (CAGR) during the forecast period?
•    What are the key development strategies employed by the key players across various geographies?
•    What are the market trends and key developments in different geographical regions?
•    What is the role of various regulatory and governmental agencies in global in-vitro diagnostics market across various geographical locations?
•    What are the major consumer preferences while purchasing or undergoing an IVD test?

The report includes the company profiles for leading players in the IVD market which enables the readers understand the current competitive scenario that prevails in this industry. Some of the key player include Thermo Fisher, Roche, Abbott, Siemens Healthineers, Becton, Dickinson, Johnson & Johnson, Qiagen, and Danaher Corporation.

TABLE OF CONTENT
Executive Summary
1 Research Scope and Methodology
1.1 Scope of the Report
1.2 Global IVD Market Research Methodology
2 Market Overview
2.1 Global IVD Market Overview (Addressable Market Size and Growth Potential), 2015-2023
2.1.1 North America
2.1.2 Europe
2.1.3 Asia Pacific
2.1.4 Latin America
2.1.5 Middle East and Africa
2.2 Historical Trends
2.3 World Economic Outlook of IVD Market, 2016
2.3.1 Global Diagnostics Expenditures
2.3.2 Global Laboratory Expenditure
2.3.3 Pricing Patterns for Diagnostics (IVD)
2.4 Technology Trends
2.4.1 An Era of Point of Care Testing
2.4.2 Exome Sequencing
2.4.3 Importance of Metabolomics profiling
2.4.4 Upsurge in the Adoption of Liquid Biopsy/Cell Free DNA Solutions
2.4.5 Emergence of Multigene Panels
2.5 Legal & Regulatory Environment
2.5.1 FDA Regulation
2.5.1.1 Key Aspect of IVD Regulation
2.5.2 European Commission Regulation
2.5.2.1 Key Changes in EU IVD Regulation
3 Market Dynamics
3.1 Market Drivers
3.1.1 Demand for Rapid, Minimally Invasive and Non-Invasive Diagnostics Tools & Techniques
3.1.2 Upsurge in the Number of Patients with Infectious and Chronic Diseases
3.1.3 Increasing Global Healthcare Expenditure
3.1.4 Demand of POC Testing
3.2 Market Challenges
3.2.1 Reimbursement Challenges
3.2.2 Uncertain and Ambiguous Regulatory Environment Restraints IVD market
3.2.3 Ethical Issues
3.3 Market Opportunities
3.3.1 Upsurge in the Demand of Molecular Diagnostics
3.3.2 Epigenomics Based Diagnostics Expected to be an Emerging Segment
4 IVD Market Demand and Supply Analysis
4.1 Demand and Supply
4.2 Demand Determinant
4.3 End-User Demand and Supply
5 Competitive Insights
5.1 Key Market Developments & Strategies
5.1.1 Patent, Approvals and Certifications
5.1.2 Product Launch and Development
5.1.3 Collaborations, Joint Ventures & Partnerships
5.1.4 Mergers and Acquisitions
5.1.5 Business Expansion and Contracts
5.2 Porter’s Five Forces Analysis
5.3 Market Attractiveness Analysis of the IVD Market, by Geography
6 Global IVD Market by Product Type, 2016-2023
6.1 Overview
6.2 Instruments
6.2.1 Different Types of IVD Instruments
6.2.2 Clinical Chemistry Analyzers
6.2.2.1 Manual Photometer and Spectrophotometer
6.2.2.2 Glucose Monitoring Systems
6.2.2.3 Dedicated Glycated Hemoglobin/HbA1 Systems
6.2.2.4 Semi/Fully Automated Analyzers
6.2.2.5 Dedicated Multi-Parameter Clinical Chemistry Systems
6.2.2.6 Small Manual and Semi-Automated CC Systems
6.2.2.7 Semi-Automated CC Analyser
6.2.2.8 Medium Automated Clinical Chemistry Analyzer
6.2.2.9 Large Automated CC Analyser
6.2.2.10 Electrolyte- Flame Photometer
6.2.2.11 Electrolyte/ISE Only
6.2.2.12 Biogas Analyzer
6.2.2.13 Urine Analyzer
6.2.3 Immunochemistry Instruments
6.2.3.1 Immunoassay Analyzer
6.2.3.2 Nucleic Acid Processors
6.2.4 Haematology Instruments
6.2.4.1 Hemoglobin Analyser
6.2.5 Coagulation Systems
6.2.6 Microbiology Instruments
6.3 Reagents & Consumables
6.4 Data Management Software/Hardware
6.5 Global IVD Services Market
7 Global IVD Market by Test Type, 2016-2023
7.1 Overview
7.2 Clinical Chemistry
7.3 Immunoassays
7.4 Whole Blood Glucose Monitoring
7.5 Molecular Diagnostics
7.6 Microbiology
7.7 Anatomic Pathology
7.8 Haematology
7.9 Coagulation
7.1 Critical Care
7.11 Urinalysis
7.12 Others
8 Global IVD Market by Application Type, 2016-2023
8.1 Diabetes
8.2 Infectious diseases
8.3 Oncology/Cancer
8.4 Cardiology
8.5 Nephrology
8.6 Autoimmune Diseases
8.7 Drug Testing/Pharmacogenomics
8.8 HIV/AIDS
8.9 Women Health
8.10 Other IVD Application
9 Global IVD Market by End User Type, 2016-2023
9.1 Central Laboratories
9.2 Point-of Care (POC)
9.3 General Practitioner (GP) and Clinics
9.4 Academic Institutions
9.5 Hospitals
9.6 Others
10 Global IVD Market by Geography, 2016-2023
10.1 North America
10.1.1 U.S.
10.1.2 Canada
10.2 Europe
10.2.1 Germany
10.2.2 U.K.
10.2.3 France
10.2.4 Italy
10.2.5 Spain
10.2.6 Sweden
10.2.7 Norway
10.2.8 Switzerland
10.2.9 Austria
10.2.10 Denmark
10.2.11 Belgium
10.2.12 Portugal
10.2.13 Netherlands
10.2.14 Finland
10.2.15 Turkey
10.2.16 Rest of Europe
10.3 APAC
10.3.1 China
10.3.2 Japan
10.3.3 Australia
10.3.4 India
10.3.5 Singapore
10.3.6 Malaysia
10.3.7 Indonesia
10.3.8 South Korea
10.3.9 Vietnam
10.3.10 Rest of Asia Pacific (RoAPAC)
10.4 Latin America
10.4.1 Brazil
10.4.2 Mexico
10.4.3 Rest of Latin America
10.5 Middle East
10.5.1 Saudi Arabia
10.5.2 Israel
10.5.3 U.A.E.
10.5.4 Qatar
10.5.5 Oman
10.5.6 Bahrain
10.5.7 Kuwait
10.5.8 Rest of Middle East
10.6 Rest of the World
11 End User Perception About IVD
11.1 Key Factors Influencing Decision About IVD Market
11.2 Influence of GPs, labs and KOLs on Decision Making
11.3 Innovation Trends in IVD
11.4 Level of Competition Among Players
11.5 Perception About Pricing
11.6 Technology Preferences
11.7 Brand Perception
11.8 Selection Criteria for IVD
11.9 Information Required to Purchase a New Product
11.1 Preferred Channel for Purchasing
11.11 Reason for Preferences
12 Market Analytics & Recommendations
12.1 Product Benchmarking
12.1.1 Instruments
12.1.2 Consumables
12.1.2.1 Pregnancy Kits
12.1.3 IVD Reagents
12.2 Competitor Benchmarking
12.2.1 Clinical Chemistry Products
12.2.2 HIV Simple Assays/Rapid Diagnostics Tests (RDTs)
12.2.3 HIV Enzyme Immunoassays (EIAs)
12.2.4 HCV Enzyme Immunoassays (EIA)
12.2.5 CD4 Enumeration Technologies
12.2.6 HIV Quantitative Nucleic Acid Testing Technologies
12.2.7 HIV Qualitative Nucleic Acid Testing Technologies for HIV Diagnosis, Including Early Infant Diagnosis
12.2.8 Haematology Analyzers
13 Competitive Landscape
13.1 Market Share Analysis
13.2 Growth Share Matrix
13.3 Comprehensive Competitive Index
13.4 Supply Chain
13.5 Value Chain
14 Company Profile
14.1 F. Hoffmann-La Roche AG
14.1.1 Overview
14.1.2 Financials
14.1.2.1 Financial Summary
14.1.3 SWOT Analysis
14.2 Danaher Corporation
14.2.1 Overview
14.2.2 Financials
14.2.2.1 Financial Summary
14.2.3 SWOT Analysis
14.3 Agilent Technologies
14.3.1 Overview
14.3.2 Financials
14.3.2.1 Financial Summary
14.3.3 SWOT Analysis
14.4 Novartis International AG
14.4.1 Overview
14.4.2 Financial
14.4.2.1 Financial Summary
14.4.3 SWOT Analysis
14.5 Illumina, Inc.
14.5.1 Overview
14.5.2 Financials
14.5.2.1 Financial Summary
14.5.3 SWOT Analysis
14.6 Myriad Genetics, Inc.
14.6.1 Overview
14.6.2 Financials
14.6.2.1 Financial Summary
14.6.3 SWOT Analysis
14.7 GE Healthcare
14.7.1 Overview
14.7.2 Financials
14.7.2.1 Financial Summary
14.7.3 SWOT Analysis
14.8 Qiagen, Inc.
14.8.1 Overview
14.8.2 Financials
14.8.2.1 Financial Summary
14.8.3 SWOT Analysis
14.9 Abbott Laboratories
14.9.1 Overview
14.9.2 Financials
14.9.2.1 Financial Summary
14.9.3 SWOT Analysis
14.10 Becton, Dickinson and Company
14.10.1 Overview
14.10.2 Financials
14.10.2.1 Financial Summary
14.10.3 SWOT Analysis
14.11 GlaxoSmithKline PLC (GSK)
14.11.1 Overview
14.11.2 Financials
14.11.2.1 Financial Summary
14.11.3 SWOT Analysis
14.12 Laboratory Corporation of America Holdings
14.12.1 Overview
14.12.2 Financials
14.12.2.1 Financial Summary
14.12.3 SWOT Analysis
14.13 Thermo Fisher Scientific
14.13.1 Overview
14.13.2 Financials
14.13.2.1 Financial Summary
14.13.3 SWOT Analysis
14.14 Johnson & Johnson
14.14.1 Overview
14.14.2 Financials
14.14.2.1 Financial Summary
14.14.3 SWOT Analysis
14.15 Siemens Healthineers
14.15.1 Overview
14.15.2 Financials
14.15.2.1 Financial Summary
14.15.3 SWOT Analysis
14.16 Quest Diagnostics Incorporated
14.16.1 Overview
14.16.2 Financials
14.16.2.1 Financial Summary
14.16.3 SWOT Analysis
14.17 Bio-Rad Laboratories, Inc.
14.17.1 Overview
14.17.2 Financials
14.17.2.1 Financial Summary
14.17.3 SWOT Analysis
14.18 Ortho Clinical Diagnostics
14.18.1 Overview
14.18.2 SWOT Analysis
List of Tables
Table 2.1 Historical Trends
Table 3.1 Impact Analysis of the Market Drivers for IVD Market
Table 3.2 Impact Analysis of the Market Challenges for IVD Market
Table 4.1 Demand and Supply
Table 4.2 Demand Determinant
Table 4.3 End-User Demand and Supply
Table 5.1 Patent and Approvals
Table 5.2 Product Launch and Development
Table 5.3 Collaborations, Joint Ventures & Partnerships
Table 5.4 Mergers and Acquisitions
Table 5.5 Business Expansion and Contracts
Table 6.1 Global In-Vitro Diagnostics Market by Product, 2015-2023 ($Million)
Table 6.2 Key Market Available Analyzers
Table 6.3 Glucose Monitoring Systems
Table 6.4 Haemoglobin/HbA1 systems
Table 6.5 Dedicated Multi-Parameter Clinical Chemistry Systems
Table 6.6 Small Manual and Semi-Automated CC Systems
Table 6.7 Semi-Automated CC Analyser
Table 6.8 Medium Automated Clinical Chemistry Analyzer
Table 6.9 Large Automated CC Analyser
Table 6.10 Biogas Analyzer
Table 6.11 Urine Analyzer
Table 6.12 Immunoassay Analyzer
Table 6.13 Nucleic Acid Processors
Table 6.14 Differential Blood Cell Counter
Table 6.15 Flow Cytometer without Cell sorter
Table 6.16 Flow Cytometer with Cell Sorter
Table 6.17 Bacteriology Instruments
Table 6.18 Blood Culture Systems
Table 7.1 Global IVD Market by Test Type, 2015-2023 ($Million)
Table 7.2 Global Immunoassays Market by Test Type, 2015-2023 ($Million)
Table 7.3 Global Molecular Diagnostics Market by Test Type, 2015-2023 ($Million)
Table 7.4 Global Immunoassays Market by Test Type, 2015-2023 ($Million)
Table 8.1 Global IVD Market by Application, 2015-2023 ($Million)
Table 9.1 Global IVD Market by End-User, 2015-2023 ($Million)
Table 10.1 Global IVD Market by Geography, 2015-2023 ($Million)
Table 10.2 North America IVD Market by Test Type, 2015-2023 ($Million)
Table 10.3 U.S. IVD Market by Test Type, 2015-2023 ($Million)
Table 10.4 Canada IVD Market by Test Type, 2015-2023 ($Million)
Table 10.5 Europe IVD Market by Test Type, 2015-2023 ($Million)
Table 10.6 Europe IVD Market by Country, 2015-2023 ($Million)
Table 10.7 Germany IVD Market by Test Type, 2015-2023 ($Million)
Table 10.8 U.K. IVD Market by Test Type, 2015-2023 ($Million)
Table 10.9 France IVD Market by Test Type, 2015-2023 ($Million)
Table 10.10 Italy IVD Market by Test Type, 2015-2023 ($Million)
Table 10.11 Spain IVD Market by Test Type, 2015-2023 ($Million)
Table 10.12 Sweden IVD Market by Test Type, 2015-2023 ($Million)
Table 10.13 Norway IVD Market by Test Type, 2015-2023 ($Million)
Table 10.14 Switzerland IVD Market by Test Type, 2015-2023 ($Million)
Table 10.15 Austria IVD Market by Test Type, 2015-2023 ($Million)
Table 10.16 Denmark IVD Market by Test Type, 2015-2023 ($Million)
Table 10.17 Belgium IVD Market by Test Type, 2015-2023 ($Million)
Table 10.18 Portugal IVD Market by Test Type, 2015-2023 ($Million)
Table 10.19 Netherlands IVD Market by Test Type, 2015-2023 ($Million)
Table 10.20 Finland IVD Market by Test Type, 2015-2023 ($Million)
Table 10.21 Turkey IVD Market by Test Type, 2015-2023 ($Million)
Table 10.22 Rest of Europe IVD Market by Test, 2015-2023 ($Million)
Table 10.23 Asia Pacific IVD Market by Test Type, 2015-2023 ($Million)
Table 10.24 Asia Pacific IVD Market by Country, 2015-2023 ($Million)
Table 10.25 China IVD Market by Test Type, 2015-2023 ($Million)
Table 10.26 Japan IVD Market by Test Type, 2015-2023 ($Million)
Table 10.27 Australia IVD Market by Test Type, 2015-2023 ($Million)
Table 10.28 India IVD Market by Test Type, 2015-2023 ($Million)
Table 10.29 Singapore IVD Market by Test Type, 2015-2023 ($Million)
Table 10.30 Malaysia IVD Market by Test Type, 2015-2023 ($Million)
Table 10.31 Indonesia IVD Market by Test Type, 2015-2023 ($Million)
Table 10.32 South Korea IVD Market by Test Type, 2015-2023 ($Million)
Table 10.33 Vietnam IVD Market by Test Type, 2015-2023 ($Million)
Table 10.34 Rest of Asia Pacific IVD Market by Test Type, 2015-2023 ($Million)
Table 10.35 Latin America IVD Market by Test Type, 2015-2023 ($Million)
Table 10.36 Brazil IVD Market by Test Type, 2015-2023 ($Million)
Table 10.37 Mexico IVD Market by Test Type, 2015-2023 ($Million)
Table 10.38 Rest of Latin America IVD Market by Test Type, 2015-2023 ($Million)
Table 10.39 Middle East IVD Market by Test Type, 2015-2023 ($Million)
Table 10.40 Middle East IVD Market by Country, 2015-2023 ($Million)
Table 10.41 Israel IVD Market by Test Type, 2015-2023 ($Million)
Table 10.42 U.A.E. IVD Market by Test Type, 2015-2023 ($Million)
Table 10.43 Qatar IVD Market by Test Type, 2015-2023 ($Million)
Table 10.44 Oman IVD Market by Test Type, 2015-2023 ($Million)
Table 10.45 Bahrain IVD Market by Test Type, 2015-2023 ($Million)
Table 10.46 Kuwait IVD Market by Test Type, 2015-2023 ($Million)
Table 10.47 Rest of Middle East IVD Market by Test Type, 2015-2023 ($Million)
Table 10.48 Rest of the World IVD Market by Test Type, 2015-2023 ($Million)
Table 12.1 Instruments
Table 12.2 Pregnancy Kits
Table 12.3 IVD Reagents
Table 12.4 Clinical Chemistry Products
Table 12.5 HIV Simple Assays/Rapid Diagnostics Tests (RDTs)
Table 12.6 HIV Enzyme Immunoassays (EIAs)
Table 12.7 HCV Enzyme Immunoassays (EIA)
Table 12.8 CD4 Enumeration Technologies
Table 12.9 HIV Quantitative Nucleic Acid Testing Technologies
Table 12.10 HIV Qualitative Nucleic Acid Testing Technologies for HIV Diagnosis, Including Early Infant Diagnosis
Table 12.11 Haematology Analyzers
List of Figures
Figure 1 Global Medical Market and IVD Market Share, 2016-2023
Figure 2 Global In-Vitro Diagnostics (IVD) Market, 2016-2023 ($Million)
Figure 3 Global In-Vitro Diagnostics Market by Geography, 2016-2023 ($Million)
Figure 4 Global In-Vitro Diagnostics Market, 2016-2023 ($Million)
Figure 5 Global In-Vitro Diagnostics Market by Product, 2016-2023 ($Million)
Figure 6 Global In-Vitro Diagnostics Market by Test Type, 2016-2023 ($Million)
Figure 7 Global In-Vitro Diagnostics Market Growth, 2016-2023 ($Million)
Figure 8 Global In-Vitro Molecular Diagnostics Market by Test, 2016-2023 ($Million)
Figure 9 Global In-Vitro Diagnostics Market by Geography, 2016 ($Million)
Figure 10 Global In-Vitro Diagnostics Market Growth, 2016-2023 ($Million)
Figure 11 Market Share Analysis, 2016
Figure 1.1 Research Methodology
Figure 1.2 Secondary Data Sources
Figure 1.4 Assumptions and Limitations
Figure 2.1 Global IVD Market by Region, 2015-2023
Figure 2.2 Global IVD Market Growth by Region, 2017-2023
Figure 2.3 Global IVD Market by Region Disease Condition, 2016
Figure 3.1 Market Dynamics
Figure 5.1 Key Market Developments & Strategies
Figure 5.2 Recent Market Development Strategy Snapshot Analysis
Figure 5.3 Porter’s Five Forces Analysis for Global IVD Market
Figure 5.4 Market Attractiveness Global IVD Market
Figure 6.1 Global IVD Consumable Market, 2015-2023 ($Million)
Figure 6.2 Global IVD Consumable Market, 2015-2023 ($Million)
Figure 6.3 Global IVD Services Market
Figure 7.1 Global Clinical Chemistry Market, 2015-2023 ($Million)
Figure 7.2 Global Whole glucose Monitoring Market, 2015-2023 ($Million)
Figure 7.3 Global Molecular Diagnostics Market, 2015-2023 ($Million)
Figure 7.4 Global Microbiology Market, 2015-2023 ($Million)
Figure 7.5 Global Anatomic Pathology Market, 2015-2023 ($Million)
Figure 7.6 Global Haematology Market, 2015-2023 ($Million)
Figure 7.7 Global Coagulation Market, 2015-2023 ($Million)
Figure 7.8 Global Critical Care Market, 2015-2023 ($Million)
Figure 7.9 Global Urinalysis Market, 2015-2023 ($Million)
Figure 7.10  Global Others Market, 2015-2023 ($Million)
Figure 8.1 Global Others Market, 2015-2023 ($Million)
Figure 8.2 Global Infectious Disease Market, 2015-2023 ($Million)
Figure 8.3 Global Oncology/Cancer Market, 2015-2023 ($Million)
Figure 8.4 Global Cardiology Market, 2015-2023 ($Million)
Figure 8.5 Global Nephrology Market, 2015-2023 ($Million)
Figure 8.6 Global Autoimmune Market, 2015-2023 ($Million)
Figure 8.7 Global Drug Testing and Pharmacogenomics Market, 2015-2023 ($Million)
Figure 8.8 Global HIV/AIDS Market, 2015-2023 ($Million)
Figure 8.9 Global Women Health Market, 2015-2023 ($Million)
Figure 8.10  Global Other IVD Application Market, 2015-2023 ($Million)
Figure 9.1 Global Central Laboratories Market, 2015-2023 ($Million)
Figure 9.2 Global Point of Care Market, 2015-2023 ($Million)
Figure 9.3 Global General practitioners and clinics serve Market, 2015-2023 ($Million)
Figure 9.4 Global Academic Institutions IVD Market, 2015-2023 ($Million)
Figure 9.5 Global Hospital IVD Market, 2015-2023 ($Million)
Figure 9.6 Global Other IVD Market, 2015-2023 ($Million)
Figure 10.1 Global IVD Market by Geography
Figure 10.2 North America IVD Market, 2015-2023 ($Million)
Figure 10.3 North America IVD Market by Country, 2015-2023 ($Million)
Figure 10.4 U.S. Immunoassays Market by Test Type, 2015-2023 ($Million)
Figure 10.5 U.S. Molecular Diagnostics Market by Test ($Million), 2015-2023
Figure 10.6 Canada Immunoassays Market Value by Test Type, 2015-2023 ($Million)
Figure 10.7 Canada Molecular Diagnostics Market Value by Test, 2015-2023 ($Million)
Figure 10.8 Europe IVD Market, 2015-2023 ($Million)
Figure 10.9 Germany Immunoassays Market by Test Type, 2015-2023 ($Million)
Figure 10.10 Germany Molecular Diagnostics Market by Test Type, 2015-2023 ($Million)
Figure 10.11 U.K. Immunoassays Market by Test Type, 2015-2023 ($Million)
Figure 10.12 U.K. Molecular Diagnostics Test Market Value by Test ($Million), 2015-2023
Figure 10.13 Immunoassays Market by Test Type, 2015-2023 ($Million)
Figure 10.14 France Molecular Diagnostics Market by Test Type, 2015-2023 ($Million)
Figure 10.15 Rest of Europe Immunoassays Market by Test Type, 2015-2023 ($Million)
Figure 10.16 Rest of Europe Molecular Diagnostics Market by Test Type, 2015-2023 ($Million)
Figure 10.17 Asia Pacific IVD Market, 2015-2023 ($Million)
Figure 10.18 China Immunoassays Market by Test Type, 2015-2023 ($Million)
Figure 10.19 China Molecular Diagnostics Market by Test Type, 2015-2023 ($Million)
Figure 10.20 Japan Immunoassays Market by Test Type, 2015-2023 ($Million)
Figure 10.21 Japan Molecular Diagnostics Market by Test Type, 2015-2023 ($Million)
Figure 10.22 Australia Immunoassays Market by Test Type, 2015-2023 ($Million)
Figure 10.23 Australia Molecular Diagnostics Market by Test Type, 2015-2023 ($Million)
Figure 10.24 Rest of Asia Pacific Immunoassays Market by Test Type, 2015-2023 ($Million)
Figure 10.25 Rest of Asia Pacific Molecular Diagnostics Market by Test Type, 2015-2023 ($Million)
Figure 10.26 Latin America IVD Market, 2015-2023 ($Million)
Figure 10.27 Latin America IVD Market by Country, 2015-2023 ($Million)
Figure 10.28 Brazil Immunoassays Market by Test Type, 2015-2023 ($Million)
Figure 10.29 Brazil Molecular Diagnostics Market by Test Type, 2015-2023 ($Million)
Figure 10.30 Rest of Latin America Immunoassays Market by Test Type, 2015-2023 ($Million)
Figure 10.31 Rest of Latin America Molecular Diagnostics Market by Test Type, 2015-2023 ($Million)
Figure 10.32 Middle East IVD Market, 2015-2023 ($Million)
Figure 10.33 Saudi Arabia Immunoassays Market by Test Type, 2015-2023 ($Million)
Figure 10.34 Saudi Arabia Molecular Diagnostics Market by Test Type, 2015-2023 ($Million)
Figure 10.35 Rest of Middle East Immunoassays Market by Test Type, 2015-2023 ($Million)
Figure 10.36 Rest of Middle East Molecular Diagnostics Market by Test Type, 2015-2023 ($Million)
Figure 10.37 Rest of the World IVD Market, 2015-2023 ($Million)
Figure 13.1 Global In-Vitro Diagnostics Market Share, 2015
Figure 13.2 Global In-Vitro Diagnostics Market Share, 2016
Figure 13.3 Global In-Vitro Diagnostics Growth Share Matrix, 2015
Figure 13.4 Global In-Vitro Diagnostics Growth Share Matrix, 2016
Figure 13.5 Global In-Vitro Diagnostics Market CCI Value, 2015
Figure 13.6 Supply Chain Share
Figure 13.7 Supply Chain
Figure 13.8 Value Chain
Figure 14.1 Roche AG: Overall Financials, (2013–2016)
Figure 14.2 Roche AG: Revenue across Different Geographies, (2013-2016)
Figure 14.3 Roche AG: Net Revenue by Business Segment, (2013-2016)
Figure 14.4 Roche AG: Revenue by Diagnostics Division (2013-2016)
Figure 14.5 Roche AG: SWOT Analysis
Figure 14.6 Danaher Corporation: Overall Financials, (2013-2016)
Figure 14.7 Danaher Corporation: Revenue across Different Geographies, (2013-2015)
Figure 14.8 Danaher Corporation: Net Revenue by Business Segment, (2013-2015)
Figure 14.9 Danaher Corporation: Net Revenue share by Business Segments, (2016)
Figure 14.10 Danaher: SWOT Analysis
Figure 14.11 Agilent Technologies: Overall Financials, (2013-2016)
Figure 14.12 Agilent Technologies: Net Revenue by Business Segment, (2013-2016)
Figure 14.13 Agilent Technologies: Revenue across Different Geographies, (2013-2015)
Figure 14.14 Agilent Technologies: SWOT Analysis
Figure 14.15 Novartis International AG: Overall Financials, (2013-2016)
Figure 14.16 Novartis International AG: Net Revenue by Business Segments, (2013–2016)
Figure 14.17 Novartis International AG: Revenue across Different Geographies, (2013–2016)
Figure 14.18 Novartis International AG: SWOT Analysis
Figure 14.19 Illumina, Inc.: Overall Financials, 2013-2016
Figure 14.20 Illumina, Inc.: Net Revenue by Business Segment, 2013-2015
Figure 14.21 Illumina, Inc.: Revenue across Different Geographies, 2013-2015
Figure 14.22 Illumina, Inc.: SWOT Analysis
Figure 14.23 Myriad Genetics: Overall Financials, (2013-2016)
Figure 14.24 Myriad Genetics: Net Revenue by Business Segments, (2013-2016)
Figure 14.25 Myriad Genetics Inc.: SWOT Analysis
Figure 14.26 GE Corporation: Net Revenue (2013-2016)
Figure 14.27 GE Corporation: Segment-Wise Net revenue 2013-2015 ($Million)
Figure 14.28 GE Healthcare: Net Revenue 2013-15 ($Billion)
Figure 14.29 GE Healthcare: Geographical Revenue, 2015
Figure 14.30 GE Healthcare: Geographical Revenue, 2015
Figure 14.31 GE Healthcare: Sub-Segment Revenues, 2015
Figure 14.32 GE Healthcare: Sub-Segment Revenues, 2015
Figure 14.33 Qiagen, Inc.: Overall Financials, (2013-2015)
Figure 14.34 Qiagen, Inc.: Revenue across Different Geographies, (2013-2015)
Figure 14.35 Qiagen, Inc.: Net Revenue by Business Segments, (2013-2015)
Figure 14.36 SWOT: Qiagen Inc.
Figure: 14.37 Abbott Laboratories: Overall Financials, (2013-2016)
Figure 14.38 Abbott Laboratories: Net revenue by Business Segments, (2013-2016)
Figure 14.39 Abbott Laboratories: Net Revenue by Diagnostics, 2016
Figure 14.40 Abbott Laboratories: Revenue across Different Geographies, (2013-2016)
Figure 14.41 Abbott Laboratories: SWOT Analysis
Figure 14.42 Becton, Dickinson and Company: Overall Financials, (2013-2016)
Figure 14.43 Becton, Dickinson And Company: Revenue across Different Geographies, (2013-2016)
Figure 14.44 Becton, Dickinson And Company: Net Revenue by Business Segment, (2013-2016)
Figure 14.45 Becton, Dickinson And Company: SWOT Analysis
Figure 14.46 GSK: Overall Financials, (2013-2016)
Figure 14.47 GSK: Revenue across Different Geographies, (2013-2016)
Figure 14.48 GSK: Net Revenue by Business Segment, (2013-2016)
Figure 14.49 GSK: Net Revenue by Therapeutics, (2013-2016)
Figure 14.50 GSK: SWOT Analysis
Figure 14.51 Laboratory Corporation of America Holdings: Overall Financials, 2013-2015
Figure 14.52 Laboratory Corporation of America Holdings: Net Revenue by Business Segment, 2013-2015
Figure 14.53 Laboratory Corporation of America Holdings: SWOT Analysis
Figure 14.54 Thermo Fisher Scientific: Overall Financials, (2013-2016)
Figure 14.55 Thermo Fisher Scientific: Net Revenue by Business Segments, (2013-2016)
Figure 14.56 Thermo Fisher Scientific: Net Revenue by Geography, (2013-2015)
Figure 14.57 Thermo Fisher Scientific: SWOT Analysis
Figure 14.58 J&J: Overall Financials 2013-2015 ($Billion)
Figure 14.59 J&J: Net revenue by segment 2013 - 2015 ($Billion)
Figure 14.60 J&J: Net revenue by Region 2013 - 2015 ($Billion)
Figure 14.61 J&J: Net revenue by SUB-SEGMENT 2013 - 2015 ($Million)
Figure 14.62 Siemens Healthineers: Overall Financials, (2013-2016)
Figure 14.63 Siemens Healthineers: Revenue across Different Geographies, (2013-2016)
Figure 14.64 Siemens Healthineers: Net Revenue by Business Segment, (2014-2016)
Figure 14.65 Siemens Healthineers: SWOT Analysis
Figure 14.66 Quest Diagnostics: Overall Financials, (2013-2016)
Figure 14.67 Quest Diagnostics: Net Revenue by Business Segments, (2013-2016)
Figure 14.68 Quest Diagnostics: SWOT Analysis
Figure 14.81 Bio-Rad Laboratories, Inc.: Overall Financials, (2014-2016)
Figure 14.82 Bio-Rad Laboratories, Inc.: Revenue across Different Geographies, (2014-2016)
Figure 14.83 Bio-Rad Laboratories, Inc.: Net Revenue by Business Segment, (2014-2016)
Figure 14.84 Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 14.85 Ortho Clinical Diagnostics: SWOT Analysis

The In-Vitro Diagnostic (IVD) sector is playing a central role in the shifting the healthcare and drug discovery landscape.  Invigorated by the demand for changes in the healthcare environment and driven by a wave of molecular advances, the in-vitro diagnostic sector is actively engaged in innovation of new tools and technologies. Present day healthcare systems are already strained under the burden of a rising demand and soaring costs; and this trend is projected to exacerbate in coming years. The current challenges tend to be chronic age-related conditions such as cardiovascular diseases, cancer, and neurological diseases, and these will grow more prevalent as population demographics shift upwards. The increase in healthcare costs due to these conditions creates a need for improved tools for clinical decision-making—ones that are more specific, faster, more accurate, more informative, more affordable and less invasive than those in current practice. These tools hold promise to help shift the emphasis in medicine from reaction to prevention.

IVD is expected to increase to $76 billion by 2023 and increase its influence over healthcare spending globally. The category’s rate of growth is accelerating due to a number of key macro forces, such as demand from emerging economies, aging population, evolving clinician attitudes, and a much needed push towards theranostics and personalized medicine. The molecular diagnostics (MDx) segment has continually outperformed the broader IVD category, and is a key driver of this market’s growth. IVD is uniquely positioned at the convergence of the life science and healthcare sectors. Diagnostics provide 60-70% of all the information doctors use worldwide, but make up just 2% of current global healthcare spending. Molecular diagnostics offer critical, personalized information to inform patient care. Diagnostics information is driving an increasing proportion of healthcare expenditure. 

The MDx market is projected to grow at the fastest CAGR projected at 7.3%. Commercial introduction of innovative technologies will be the key driver of growth in these segments. Tools enabling earlier, more accurate diagnosis, improved treatment decision and better treatment monitoring will encourage further adoption of innovation.  Automation has been the driving growth across almost all segments.

While the Infectious and Blood Screening markets are showing initial signs of development, significant growth is occurring in the Oncology and Genetic segments. Clinical validation of molecular tests and associated biomarkers are creating new emergent markets (e.g. HIV tests) and replacing some existing IVD assays. Genomics, proteomics, and metabolomics have generated a new source of biomarkers that are increasingly gaining clinical acceptance. Oncology is expected to comprise roughly 30% of the overall MDx spending in IVD by 2023.

Immunoassays are testing procedures that employ specific antibody binding for measuring an analyte in a test sample. Since the mid-1960s, immunoassays continue to make a major contribution to clinical lab. In 2016, immunoassays of all types (automated, manual, ELISAs, enzyme immunoassays, bead arrays, and microarrays) dominate the IVD products offerings and represent about a third of the testing in the clinical laboratory. Immunoassays have become one of the primary and indispensable tools in the diagnosis and monitoring of all areas of medicine. By 2023, the market for immunoassay test market will grow by 5.9% annually.

Figure 9
Global In-Vitro Diagnostic Market by Geography, 2016 ($Million)

Global In-Vitro Diagnostic Market by Geography, 2016 ($Million)

 BIS Research Analysis

Complicated and limited availability of reimbursement options will restrain the growth of the market. The emergence of epigenomics-based diagnostics is expected to drive the IVD market in the future. The ability of molecular diagnostics to detect diseases at an early stage of development will also fuel the future growth of the market.

North America’s huge market share is attributed to the well-structured healthcare system in the U.S. and Canada as well as to the large amount of public as well as private healthcare expenditure. The presence of a large patient pool and the increasing healthcare expenditure in the Asia-Pacific region are particularly fueling the growth in this market. Asia-Pacific is expected to outperform all geographies in terms of growth and is expected to grow at a CAGR of 5.7% from 2017 to 2023.

In 2015, Roche Diagnostics, Siemens Healthcare, Abbott Laboratories, and Danaher had 47.5% of the market share. There are a number of future challenges for both the market leaders and niche suppliers. Large global IVD companies will continue expansion through acquisition, but will struggle to deliver organic growth, which also occurred in 2012. The competition will further intensify for niche suppliers as growing numbers of their customers, namely physician practitioners, are unable to maintain their profitability.

We understand that your business need specific answers pertaining to the market. And , therefore, we do provide customised research tailored to your need.

With the purchase of this report, you are entitled to certain degree of free customisation within the scope of the study.

Do get in touch to help us understand how we can serve u better with a custom solution to your research needs. We assure quick turnaround for your pressing business requirements.

Contact Information


Name *
Email *
 
Company Name *
Designation
 
 
Contact No. *
Other Details
 
 

Write the characters in the image above
 
 
* Required Fields

OUR HAPPY CLIENTS


related reports

 

OUR CLIENTS